Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Symbol: NASDAQ:CPHR
- CUSIP: N/A
- Web: www.cipherpharma.com
- 50 Day Moving Avg: $2.99
- 200 Day Moving Avg: $2.98
- 52 Week Range: $2.55 - $6.25
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 149.51
- P/E Growth: 0.0000
- Net Margins: -64.97%
- Return on Equity: -9.83%
- Return on Assets: -4.40%
- Debt-to-Equity Ratio: 1.22%
- Current Ratio: 2.59%
- Quick Ratio: 2.50%
Frequently Asked Questions for Cipher Pharmaceuticals (NASDAQ:CPHR)
What is Cipher Pharmaceuticals' stock symbol?
Cipher Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPHR."
How were Cipher Pharmaceuticals' earnings last quarter?
Cipher Pharmaceuticals Inc (NASDAQ:CPHR) announced its earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.06. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $10.87 million. Cipher Pharmaceuticals had a negative return on equity of 9.83% and a negative net margin of 64.97%. View Cipher Pharmaceuticals' Earnings History.
Where is Cipher Pharmaceuticals' stock going? Where will Cipher Pharmaceuticals' stock price be in 2017?
2 brokerages have issued 1-year price objectives for Cipher Pharmaceuticals' stock. Their predictions range from $3.50 to $3.50. On average, they expect Cipher Pharmaceuticals' stock price to reach $3.50 in the next twelve months. View Analyst Ratings for Cipher Pharmaceuticals.
Who are some of Cipher Pharmaceuticals' key competitors?
Some companies that are related to Cipher Pharmaceuticals include Novo Nordisk A/S (NVO), Teva Pharmaceutical Industries Ltd (TEVA), Dr.Reddy's Laboratories Ltd (RDY), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), Endo International plc - (ENDP), Amarin Co. plc (AMRN), Synergy Pharmaceuticals (SGYP), Amphastar Pharmaceuticals (AMPH), Depomed (DEPO), SciClone Pharmaceuticals (SCLN), Sucampo Pharmaceuticals (SCMP), DURECT (DRRX), Summit Therapeutics PLC (SMMT), Merus Labs International (MSLI), Cardiome Pharma Corp (CRME), Cumberland Pharmaceuticals (CPIX) and Albireo Pharma (ALBO).
How do I buy Cipher Pharmaceuticals stock?
Shares of Cipher Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Cipher Pharmaceuticals stock cost?
One share of Cipher Pharmaceuticals stock can currently be purchased for approximately $2.99.
Earnings History for Cipher Pharmaceuticals (NASDAQ:CPHR)Earnings History by Quarter for Cipher Pharmaceuticals (NASDAQ:CPHR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/11/2016||Q316||($0.10)||($0.08)||$10.42 million||$9.30 million||View||N/A|
|5/5/2016||Q116||($0.04)||($0.10)||$10.87 million||$9.10 million||View||N/A|
|11/4/2015||Q3 2015||$0.07||($0.04)||$12.50 million||$8.46 million||View||N/A|
|8/14/2015||Q2 2015||$0.02||$0.01||$11.50 million||$8.84 million||View||N/A|
|5/13/2015||Q115||$0.17||$0.10||$7.88 million||$9.18 million||View||N/A|
|2/25/2015||Q4 2014||$0.12||$0.11||$6.72 million||View||N/A|
Earnings Estimates for Cipher Pharmaceuticals (NASDAQ:CPHR)
2017 EPS Consensus Estimate: $0.04
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Cipher Pharmaceuticals (NASDAQ:CPHR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Cipher Pharmaceuticals (NASDAQ:CPHR)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Cipher Pharmaceuticals (NASDAQ:CPHR)
Latest Headlines for Cipher Pharmaceuticals (NASDAQ:CPHR)
Cipher Pharmaceuticals (CPHR) Chart for Friday, May, 26, 2017